XML 41 R28.htm IDEA: XBRL DOCUMENT v3.23.1
Share-Based Compensation (Tables)
3 Months Ended
Mar. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Summary of Recognition of Share-Based Compensation related to Employees

Share-based compensation expense is recognized in cost of services, product and technology expense, and selling, general, and administrative expense, in the accompanying condensed consolidated statements of operations and comprehensive income as follows (in thousands):

 

 

Three Months Ended March 31,

 

 

 

2023

 

 

2022

 

Share-based compensation expense

 

 

 

 

 

 

Cost of services

 

$

275

 

 

$

274

 

Product and technology expense

 

 

457

 

 

 

204

 

Selling, general, and administrative expense

 

 

1,326

 

 

 

1,381

 

Total share-based compensation expense

 

$

2,058

 

 

$

1,859

 

Summary of outstanding stock option grants issued

A summary of the option and profits interests activity for the three months ended March 31, 2023 is as follows

 

 

 

 

Options

 

 

Weighted Average
Exercise Price

 

 

Weighted Average Remaining Contractual Term

 

Aggregate Intrinsic Value

December 31, 2022

 

Grants outstanding

 

 

2,843,342

 

 

$

6.66

 

 

 

 

 

 

 

Grants exercised

 

 

(85,760

)

 

$

6.68

 

 

 

 

 

 

 

Grants cancelled/forfeited

 

 

(250,856

)

 

$

6.69

 

 

 

 

 

March 31, 2023

 

Grants outstanding

 

 

2,506,726

 

 

$

6.66

 

 

6.8 Years

 

$18.3 million

March 31, 2023

 

Grants vested

 

 

806,379

 

 

$

6.64

 

 

6.6 Years

 

$5.9 million

March 31, 2023

 

Grants unvested

 

 

1,700,347

 

 

$

6.67

 

 

 

 

 

2021 Equity Plan [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Summary of Assumptions Applied to Establish Fair Value of Options Granted Using Black-Scholes Option Pricing Model

The fair value for stock options granted for the three months ended March 31, 2023 was estimated at the date of grant using the Black-Scholes option-pricing model with the following weighted average assumptions:

 

 

Options

 

Expected stock price volatility

 

 

35.48

%

Risk-free interest rate

 

 

4.22

%

Expected term (in years)

 

 

6.25

 

Fair-value of the underlying unit

 

$

13.70

 

Summary of Option Unit Activity

A summary of the option activity for the three months ended March 31, 2023 is as follows:

 

 

 

 

Options

 

 

Weighted Average
Exercise Price

 

 

Weighted Average Remaining Contractual Term

 

Aggregate Intrinsic Value

 

December 31, 2022

 

Grants outstanding

 

 

4,311,662

 

 

$

15.24

 

 

 

 

 

 

 

 

Grants issued

 

 

71,099

 

 

$

13.70

 

 

 

 

 

 

March 31, 2023

 

Grants outstanding

 

 

4,382,761

 

 

$

15.21

 

 

8.4 Years

 

$0.0 million

 

March 31, 2023

 

Grants vested

 

 

1,392,123

 

 

$

15.16

 

 

8.3 Years

 

 

 

March 31, 2023

 

Grants unvested

 

 

2,990,638

 

 

$

15.23

 

 

 

 

 

 

 

Summary of the RSU activity

A summary of the restricted stock units (“RSU”) activity for the three months ended March 31, 2023 is as follows:

 

 

 

 

Shares

 

 

Weighted Average
Grant Date Fair Value

 

December 31, 2022

 

Nonvested RSUs

 

 

472,332

 

 

$

16.00

 

 

 

Granted

 

 

21,202

 

 

$

13.70

 

 

 

Vested

 

 

(5,077

)

 

$

16.33

 

March 31, 2023

 

Nonvested RSUs

 

 

488,457

 

 

$

15.90

 

2021 Equity Plan [Member] | Restricted Stock [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Summary of Restricted Stock Activity

A summary of the restricted stock activity for the three months ended March 31, 2023 is as follows:

 

 

 

 

Shares

 

 

Weighted Average
Grant Date Fair Value

 

December 31, 2022

 

Nonvested restricted stock

 

 

2,281,300

 

 

$

3.85

 

 

 

Vested

 

 

(326,670

)

 

$

3.85

 

March 31, 2023

 

Nonvested restricted stock

 

 

1,954,630

 

 

$

3.85